The biopharmaceutical company Actinium Pharmaceuticals, Inc., which is focused on developing immunotherapeutics for cancer, has entered into a manufacturing supply agreement with Goodwin Biotechnology, Inc. Goodwin will oversee the current cGMP production of a monoclonal antibody anticipated to be used in an upcoming Phase III clinical trial of Iomabâ„¢-B. Iomabâ„¢-B will be used in preparing patients for hematopoietic stem cell transplant commonly referred to as bone marrow transplant.

Source: Goodwin Biotechnology